Zanubrutinib

SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release.

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

Healio spoke with Ryan. W. Jacobs, MD, about recent advancements in the management of CLL.

CHICAGO – In this Healio video exclusive, Christopher Flowers, MD, discusses how the combination of zanubrutinib and obinutuzumab vs. obinutuzumab alone leads to longer PFS in patients with relapsed/refractory follicular lymphoma.